Global Biochip Product Market 2022 Growth, Trend, Analysis, Future Opportunities and Industry Forecast to 2030

SDKI Inc. published a new report on the biochip product market. This study includes the statistical and analytical approaches needed to grow the biochip product market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-59123

The biochip product market is estimated to reach US $ 69.10 billion by 2030 from a market value of US $ 21.06 billion in 2022 and is expected to grow at a CAGR of 18.5% during the 2022-2030 forecast period.

Recently, the demand for biochip products has grown significantly in the healthcare field. A biochip is a type of miniaturized medical device used to simultaneously perform multiple biochemical reactions in a molecular laboratory. Biochips are often used for rapid screening of biological analyzes in a wide range of applications such as drug screening and development, molecular diagnostics, etc. It is designed with the help of microarrays and microfluidics technology, in which digital microfluidic biochips are extremely effective and have gained immense popularity in the biochemical field.

In addition, Biochip has several unique features such as integrated intelligence, speed, low cost, complexity and redundancy. Due to these advantages, they are widely used to detect cancer and other diseases, and to provide personalized medicine in the industry. Therefore, increased prevalence of cancer and immune disorders, increased adoption of personalized medicine, and an increasing elderly population are key factors driving the growth of the biochip product market during the forecast period. According to the International Agency for Research on Cancer (IARC), in 2018, approximately 17 million new cancer cases and 9.5 million cancer deaths were registered worldwide. In addition, the global burden of cancer is expected to increase to approximately 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. This is expected to accelerate the demand for biochip products for cancer cell screening. Therefore, it contributes to the growth of the biochip product market.

Report sample URL
https://www.sdki.jp/sample-request-59123

However, the high cost of biochips and the lack of awareness in emerging markets could hinder the growth of the biochip product market during the 2022-2030 forecast period.

Biochip Product Market Segment

The biochip product market is by type (DNA chips, Lab-on-a-Chip, protein chips, other arrays), manufacturing technology (microarrays, microfluidics), and end users (biotechnology). And pharmaceutical companies, hospitals and diagnostic centers, academic research institutes, etc.) and by region. These segments are further sub segmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Regional Overview of the Biochip Products Market

The North American region is the world's leading region in terms of market share. This is due to the increased prevalence of lifestyle-related and heart disease and the presence of well-developed medical infrastructure in the region. Meanwhile, the Asia Pacific biochip product market is expected to register the largest CAGR during the 2022-2030 forecast period. This is due to the aging of the population and increasing patient awareness of biochips in countries such as China and India. In addition, the rapid growth of the life sciences industry in China and India, as well as the growth of biotechnology and pharmaceutical research, are also contributing to the growth of the biochip product market in the region.

These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, Other Asia Pacific); Latin America (Brazil, Mexico, Argentina, etc.) Latin America); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy) , Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more. Key Players in the Biochip Products Market

Details of the survey report
https://www.sdki.jp/press-details/global-biochips-product-market/44

Key players in the biochip products market include Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer, Inc., Fluidigm Corporation, Illumina, Inc., GE Healthcare, Bio-Rad Laboratories. Inc., Cepheid Inc., Thermo Fisher Scientific, Inc., Roche Diagnostics and more. The survey includes a detailed competitive analysis of these major companies in the biochip product market, corporate profiles, recent developments, and key market strategies.

Contact Us

Hina Miyazu
15/F Cerulean Tower, 26-1 Sakuragaoka-cho
Tokyo, Shibuya-ku, Japan
+ 81345720790
sales@sdki.jp

SDKI Inc. Company Profile

SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

This release was published on openPR.